메뉴 건너뛰기
Diseases of the Colon and Rectum
Volumn 50, Issue 3, 2007, Pages 395-398
Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: Report of a case
Author keywords

Anal cancer; Cetuximab; Erbitux
Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN;
EID: 33847776767     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-006-0786-9     Document Type: Article
Times cited : (39)
References (11)
  • 3
    • 0029790837 scopus 로고    scopus 로고
    • Anal canal cancer: Current treatment and results
    • BJ Cummings 1996 Anal canal cancer: current treatment and results Ann Acad Med Singapore 25 460 467
    • (1996) Ann Acad Med Singapore , vol.25 , pp. 460-467
    • Cummings, B.J.1
  • 4
    • 0020575415 scopus 로고
    • Combined preoperative radiation and chemotherapy for squamous-cell carcinoma of the anal canal
    • ND Nigro HG Seydel B Considine 1983 Combined preoperative radiation and chemotherapy for squamous-cell carcinoma of the anal canal Cancer 51 1826 1829
    • (1983) Cancer , vol.51 , pp. 1826-1829
    • Nigro, N.D.1    Seydel, H.G.2    Considine, B.3
  • 5
    • 0038673856 scopus 로고    scopus 로고
    • The role of growth factor signaling in malignancy
    • RS Herbst A Onn J Mendelsohn 2003 The role of growth factor signaling in malignancy Cancer Treat Res 115 19 72
    • (2003) Cancer Treat Res , vol.115 , pp. 19-72
    • Herbst, R.S.1    Onn, A.2    Mendelsohn, J.3
  • 6
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • F Kabbinavar HI Hurwitz L Fehrenbacher 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3
  • 7
    • 1242273868 scopus 로고    scopus 로고
    • Cetuximab in cancers of the lung and head & neck
    • ES Kim EE Vokes MS Kies 2004 Cetuximab in cancers of the lung and head & neck Semin Oncol 31 61 67
    • (2004) Semin Oncol , vol.31 , pp. 61-67
    • Kim, E.S.1    Vokes, E.E.2    Kies, M.S.3
  • 8
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 9
    • 0036605053 scopus 로고    scopus 로고
    • Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck Squamous-cell carcinoma lines
    • CC Bancroft Z Chen J Yeh 2002 Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck Squamous-cell carcinoma lines Int J Cancer 99 538 548
    • (2002) Int J Cancer , vol.99 , pp. 538-548
    • Bancroft, C.C.1    Chen, Z.2    Yeh, J.3
  • 10
    • 0035173157 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance
    • D Busse FM Yakes AE Lenferink 2001 Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance Semin Oncol 28 47 55
    • (2001) Semin Oncol , vol.28 , pp. 47-55
    • Busse, D.1    Yakes, F.M.2    Lenferink, A.E.3
  • 11
    • 0035884231 scopus 로고    scopus 로고
    • The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
    • CL Arteaga 2001 The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 32S 40S
    • (2001) J Clin Oncol , vol.19
    • Arteaga, C.L.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.